A Phase 4 interventional study of Temozolomide and Temozolomide in Brain Neoplasms, Malignant, Primary, sponsored by Monte Verde SA. Completed at 2 sites in Argentina. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2015-04-02.
Sponsored by Monte Verde SA · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies testing temozolomide in Brain Neoplasms — 4 open to participants now, 6 under way, 1 of them phase 3. Temozolomide · Brain Neoplasms.
Among the 119 studies testing temozolomide in Brain Neoplasms, this one is the 73rd largest by enrollment of the 109 interventional ones that give a count, is one of 3 that started in 2012, is the only one in phase 4, and was the 99th registered.
2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.
Browse Brain Neoplasms studies →4 of the 119 studies testing temozolomide in Brain Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
Rigel Pharmaceuticals · Sites in United States, Australia, Canada and 4 more countries
Ages 12–39
Nationwide Children's Hospital · Sites in United States, Australia, Canada and 3 more countries
Ages 12 mo–39 yrs
Kari Kendra · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 18–74
By country, each count listing its studies:
Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 78 · Phase 3 9 · Phase 4 1
First in 1998; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 40 across 1,832 interventional studies indexed under Brain Neoplasms.
Median enrollment 34 across the 109 interventional studies. Of the 97 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 119 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Monte Verde SA as lead sponsor.
Monte Verde SA has 1 study filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing temozolomide in Brain Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT05588453Kari KendraNatural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain | 2027-04-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 119 studies testing temozolomide in Brain Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this crossover, single-dose, bioequivalence study is to compare the rate and extent of absorption of Temozolomide after the administration of the study product (Dralitem®, Monte Verde S.A.) and the reference product (Temodal®, Schering Plough) in primary Central Nervous System patients.
Prospective, randomized, two-period, two treatment, two-way crossover bioequivalence study of two Temozolomide oral formulations (Dralitem vs. Temodal), in primary Central Nervous System tumor patients under fasting conditions. Open label to the patients and investigators and blind to the bioanalytical and clinical laboratories.
Study plan: days -21 to 0 (Recruitment period); days 1 to 5 (Treatment period); days 6 to 21 (Safety surveillance period). Sample size: 24 patients will be randomized. The patients will be administered Temozolomide 200 mg/m2 on the first two days (Dralitem) of the treatment cycle.
They will be admitted to the study clinical site on the evening of day 2. In the morning of day 3 they will be randomized into two groups of equal size. According to the assigned random number, each subject will receive a single oral dose of Temozolomide 200mg/m2 from either Monte Verde Sociedad Anónima (SA) product (Dralitem) or from Schering-Plough product (Temodal). The single dose of 200 mg/m2 will be reached with three different Temozolomide capsule strengths: 20, 100 and 250 mg. Drugs will be administered with 200-240 ml of water in semi-sitting upright position.
The following day (day 4) each subject will receive an oral dose of Temozolomide 200 mg/m2 of the product that did not receive the day before. On days 3 and 4 after drug administration, blood samples will be obtained for pharmacokinetic evaluation. The patient will be discharged from the clinical site on day 4 after completion of sampling for pharmacokinetic analysis. On day 5, all patients will receive Temozolomide 200 mg/m2 (Dralitem).
On days 3 and 4, samples of venous blood will be withdrawn from the forearm vein of each volunteer at the following time points: 0 (pre-dose) and 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours post-dose after each period administration. The washout period between the treatment arms was 10 hours, on days 3 and 4. Samples will be processed according to the validated method MANA (Método Analítico) - PLB (Proyecto Laboratorio Bioanalítico) 004 - TEM (Temozolomide) - 01/01. Measurement of plasma concentration of Temozolomide was performed using High Performance Liquid Chromatography (HPLC) followed by detection by tandem mass spectrometry (MS / MS).
The area under the curve (AUC) and the Cmax levels of the drug vs. time will be obtained for each subject. The resulting values of the logarithmic transformation of these parameters will be used for statistical comparisons (mixed effects ANOVA). The limits of the 90% confidence interval for the ratio of log transformed pharmacokinetic parameters will be calculated. Bioequivalence criteria: each calculated confidence interval should be within the acceptance range from 80.00 to 125.00.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Temozolomide (Schering-Plough) 200 mg/m2, single oral dose.
Drug: Temozolomide
Temozolomide (Monte Verde S.A.) 200 mg/m2, single oral dose
Drug: Temozolomide
Also known as: Temodal
Also known as: Dralitem
Cmax
Rate of absorption of Temozolomide (Cmax) will be measured after the oral administration of the test product (Dralitem®, Monte Verde S.A.) or the reference product (Temodal®, Schering-Plough).
Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4
AUC0-t
Extent of absorption of Temozolomide from time (0) to the last quantifiable concentration (t) will be measured after the oral administration of the test product (Dralitem®, Monte Verde S.A.) or the reference product (Temodal®, Schering-Plough)
Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4
AUC0-∞
Extent of absorption of Temozolomide from time (0) to infinity (∞) will be measured after oral administration of the test product (Dralitem®, Monte Verde S.A.) or the reference product (Temodal®, Schering-Plough).
Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4
Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)
AEs and SAEs will be collected from the start of study treatment and until two weeks post last dose. If AEs or SAEs extend in time and are not resolved before the end of the 2-week follow up period, this period shall last until the event/s are resolved.
Time frame: Up to two weeks post last dose
Kel
Rate at which Temozolomide is removed from the body.
Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4
T1/2
Time required for Temozolomide plasma concentration to decrease by 50%
Time frame: 0, 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0 hours on Days 3 and 4
This study enrolled patients with primary tumours of the Central Nervous System (CNS) excluding patients with primary CNS lymphoma, from FLENI Clinical-Surgical Diagnosis and Treatment Institute, Buenos Aires, Argentina. The last patient completed in October 2013.
| Milestone | Temodal, Then Dralitem | Dralitem, Then Temodal |
|---|---|---|
| Started | 8 | 8 |
| Received intervention | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
| Milestone | Temodal, Then Dralitem | Dralitem, Then Temodal |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
| Milestone | Temodal, Then Dralitem | Dralitem, Then Temodal |
|---|---|---|
| Started | 8 | 8 |
| Received intervention | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
Rate of absorption of Temozolomide (Cmax) will be measured after the oral administration of the test product (Dralitem®, Monte Verde S.A.) or the reference product (Temodal®, Schering-Plough).
| mcg/mL | Temodal | Dralitem |
|---|---|---|
| Cmax | 11.108 ± 2.486 | 10.575 ± 2.805 |
AEs and SAEs will be collected from the start of study treatment and until two weeks post last dose. If AEs or SAEs extend in time and are not resolved before the end of the 2-week follow up period, this period shall last until the event/s are resolved.
Results for this outcome have not been posted.
Rate at which Temozolomide is removed from the body.
| 1/h | Temodal | Dralitem |
|---|---|---|
| Kel | 0.3743 ± 0.0451 | 0.3691 ± 0.0258 |
Time required for Temozolomide plasma concentration to decrease by 50%
| hours | Temodal | Dralitem |
|---|---|---|
| T1/2 | 1.87 ± 0.20 | 1.89 ± 0.13 |
Extent of absorption of Temozolomide from time (0) to the last quantifiable concentration (t) will be measured after the oral administration of the test product (Dralitem®, Monte Verde S.A.) or the reference product (Temodal®, Schering-Plough)
| mcg*h/mL | Temodal | Dralitem |
|---|---|---|
| AUC0-t | 30.796 ± 3.893 | 31.104 ± 4.019 |
Extent of absorption of Temozolomide from time (0) to infinity (∞) will be measured after oral administration of the test product (Dralitem®, Monte Verde S.A.) or the reference product (Temodal®, Schering-Plough).
| mcg*h/mL | Temodal | Dralitem |
|---|---|---|
| AUC0-∞ | 31.817 ± 4.159 | 32.290 ± 4.174 |
Collected over Eighteen days for each arm (Safety Surveillance Period).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Temodal | — | 0/16 (0%) | 5/16 (31.3%) |
| Dralitem | — | 0/16 (0%) | 4/16 (25%) |
| Event | Temodal | Dralitem |
|---|---|---|
| Itchy RashSkin and subcutaneous tissue disorders | 1/16 | 0/16 |
| VomitingGastrointestinal disorders | 1/16 | 0/16 |
| GastritisGastrointestinal disorders | 1/16 | 0/16 |
| HyporexiaMetabolism and nutrition disorders | 1/16 | 0/16 |
| Leg EdemaVascular disorders | 1/16 | 0/16 |
| WeaknessNervous system disorders | 1/16 | 0/16 |
| DizzinessNervous system disorders | 1/16 | 0/16 |
| Loss of tasteNervous system disorders | 1/16 | 0/16 |
| AdynamiaNervous system disorders | 1/16 | 0/16 |
| Abdominal PainGastrointestinal disorders | 1/16 | 0/16 |
| Age, Continuous(Years) | Temodal, Then Dralitem | Dralitem, Then Temodal | Total |
|---|---|---|---|
| Mean | 53.75 ± 9.35 | 39.75 ± 14.5 | 48.44 ± 14.5 |
| Sex: Female, Male(Participants) | Temodal, Then Dralitem | Dralitem, Then Temodal | Total |
|---|---|---|---|
| Female | 4 | 3 | 7 |
| Male | 4 | 5 | 9 |
| Region of Enrollment(participants) | Temodal, Then Dralitem | Dralitem, Then Temodal | Total |
|---|---|---|---|
| Argentina | 8 | 8 | 16 |
| Height(cm) | Temodal, Then Dralitem | Dralitem, Then Temodal | Total |
|---|---|---|---|
| Mean | 169 ± 9.53 | 173.37 ± 8.65 | 170.00 ± 8.00 |
| Weight, Continuous(kg) | Temodal, Then Dralitem | Dralitem, Then Temodal | Total |
|---|---|---|---|
| Mean | 78.87 ± 14.20 | 81.12 ± 10.78 | 79.40 ± 12.00 |
| Body Surface, Continuous(m^2) | Temodal, Then Dralitem | Dralitem, Then Temodal | Total |
|---|---|---|---|
| Mean | 1.89 ± 0.22 | 1.95 ± 0.16 | 1.92 ± 0.19 |
| Body Mass Index(kg/m^2) | Temodal, Then Dralitem | Dralitem, Then Temodal | Total |
|---|---|---|---|
| Mean | 26.03 ± 2.01 | 28.46 ± 2.72 | 27.26 ± 2.82 |
The record gives a start of Jan 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Temozolomide